In Brief: Sec. 936 tax credits
Executive Summary
Sec. 936 tax credits: House Resources Committee Chairman Young (R-Alaska) is considering a five to 10 year phase-out of Sec. 936 tax credits in U.S. territories as part of a larger initiative to extend the U.S. federal tax system to its territories. GAO is analyzing the impact of implementing the federal tax system on the territories at Young's request but will not finish collecting the necessary data until mid- to late-July. Elimination or phase-out of Sec. 936 tax credits is not included in either the House or Senate budget resolutions or in the FY 1996 budget...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth